Tianjin TEDA Biomedical Engineering (8189) Fundamentals 2026 — Revenue Analysis | SniperIQ
Tianjin TEDA Biomedical Engineering (8189) is a CN-listed Basic Materials company in Agricultural Inputs with a market capitalization of HK
Tianjin TEDA Biomedical Engineering (8189) has a market capitalization of approximately HK
Tianjin TEDA Biomedical Engineering's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 21.4x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
Tianjin TEDA Biomedical Engineering runs a net profit margin of -19.8%, a gross margin of 5.2%, and an operating margin of -7.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Tianjin TEDA Biomedical Engineering reported revenue of ¥509M for fiscal year 2025, with net income of -¥88M and earnings per share (EPS) of -0.0426. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Tianjin TEDA Biomedical Engineering does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Tianjin TEDA Biomedical Engineering carries a debt-to-equity ratio of 8.98x and a current ratio of 0.75x, with a market beta of -0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tianjin TEDA Biomedical Engineering (8189) the key facts are: market cap HK
Get Tianjin TEDA Biomedical Engineering's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.